Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome
Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a
glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable of
inducing small bowel adaptation and regeneration in patients with short bowel syndrome (SBS),
with the potential to decrease parenteral nutrition dependence.